New York City-headquartered Ohr Pharmaceutical Inc.’s proposed merger with NeuBase Therapeutics Inc. was approved by Ohr’s stockholders at a special meeting. As announced on Jan. 3, 2019, the deal will create a public company under which the stockholders of Pittsburgh-based NeuBase become majority holders of the combined company.
Upon closing, the combined company will change its name to NeuBase Therapeutics Inc., and the NASDAQ trading symbol will become NBSE. The executive team of NeuBase will serve as the executive team of the combined company, led by CEO Dietrich A. Stephan, Ph.D.
NeuBase is focused on advancing its proprietary peptide-nucleic acid antisense oligonucleotide (PATrOL™) technology platform for the development of therapies to address severe and currently untreatable diseases caused by genetic mutations. The company’s lead programs are in Huntington’s disease and myotonic dystrophy.
The proposed merger remains subject to further customary closing conditions and regulatory approvals. Ohr and NeuBase expect the closing to occur during the week of July 15, 2019.
